Orthopedics M&A has been characterized by two dominant themes: the consolidation of mid-tier players seeking scale to compete with Stryker, Zimmer Biomet, and DePuy Synthes, and the acquisition of technology assets in robotics, digital surgery, and biologics. Enovis's $3.6 billion acquisition of LimaCorporate, Globus Medical's $3.1 billion merger with NuVasive, and Smith & Nephew's strategic divestitures collectively illustrate the competitive logic driving deal activity. Private equity continues to consolidate the fragmented mid-market, creating acquisition targets and competitive pressure on established players.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• M&A Transaction Analysis — Strategic Rationale, Valuations, and Competitive Implications
• Robotic Surgery and Digital Technology Acquisitions
• Biologics and Regenerative Medicine Acquisitions
• Emerging Market and Distribution Acquisitions
• Private Equity Activity — Portfolio Companies and Exit Strategies
• Partnership and Joint Venture Activity 2023–2026
• Competitive Implications — Market Share Shifts and Strategic Positioning
• Outlook — Likely Targets and Deal Activity 2026–2028
Table of Contents
1. Executive Summary
2. Overview
3. Joint Replacement M&A
4. Spine and Biologics M&A
5. Sports Medicine M&A
6. Robotics and Digital M&A
7. Financial Analysis
8. Strategic Rationale
9. Integration Outcomes
10. Outlook 2026-2028
11. Competitive Landscape
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Suppliers — Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Arthrex
DePuy Synthes
Enovis
Globus Medical
NuVasive
Smith & Nephew
Stryker
Zimmer Biomet
